Austar Lifesciences Limited Logo

Austar Lifesciences Limited

6118.HK

(1.8)
Stock Price

0,66 HKD

-1.94% ROA

-4.89% ROE

-9.76x PER

Market Cap.

400.428.135,75 HKD

64.19% DER

0% Yield

-4.14% NPM

Austar Lifesciences Limited Stock Analysis

Austar Lifesciences Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Austar Lifesciences Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (38%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

ROE in an average range (8.05%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 ROA

The stock's ROA (3%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 PBV

The stock's PBV ratio (1.06x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (208), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Austar Lifesciences Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Austar Lifesciences Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Austar Lifesciences Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Austar Lifesciences Limited Revenue
Year Revenue Growth
2013 705.153.000
2014 679.750.000 -3.74%
2015 627.544.000 -8.32%
2016 672.545.000 6.69%
2017 546.933.000 -22.97%
2018 816.585.000 33.02%
2019 1.049.021.000 22.16%
2019 1.049.021.000 0%
2020 1.295.980.000 19.06%
2021 2.015.028.000 35.68%
2022 2.228.644.000 9.59%
2023 3.857.076.000 42.22%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Austar Lifesciences Limited Research and Development Expenses
Year Research and Development Expenses Growth
2013 23.897.000
2014 23.594.000 -1.28%
2015 26.908.000 12.32%
2016 32.040.999 16.02%
2017 26.062.000 -22.94%
2018 30.308.000 14.01%
2019 42.577.000 28.82%
2019 42.577.000 0%
2020 48.268.000 11.79%
2021 65.598.000 26.42%
2022 70.163.000 6.51%
2023 109.860.000 36.13%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Austar Lifesciences Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 47.849.000
2014 57.278.000 16.46%
2015 56.213.000 -1.89%
2016 67.953.000 17.28%
2017 70.796.000 4.02%
2018 77.450.000 8.59%
2019 108.731.000 28.77%
2019 108.731.000 0%
2020 98.695.000 -10.17%
2021 128.094.000 22.95%
2022 134.614.000 4.84%
2023 346.624.000 61.16%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Austar Lifesciences Limited EBITDA
Year EBITDA Growth
2013 77.603.000
2014 91.970.000 15.62%
2015 14.484.000 -534.98%
2016 -9.657.000 249.98%
2017 -60.206.000 83.96%
2018 1.558.000 3964.31%
2019 42.481.000 96.33%
2019 14.400.000 -195.01%
2020 39.830.000 63.85%
2021 130.621.000 69.51%
2022 106.070.000 -23.15%
2023 -204.044.000 151.98%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Austar Lifesciences Limited Gross Profit
Year Gross Profit Growth
2013 214.966.000
2014 228.607.000 5.97%
2015 154.247.000 -48.21%
2016 159.707.001 3.42%
2017 121.532.000 -31.41%
2018 204.394.000 40.54%
2019 284.244.000 28.09%
2019 284.244.000 0%
2020 323.530.000 12.14%
2021 479.008.000 32.46%
2022 462.669.000 -3.53%
2023 589.092.000 21.46%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Austar Lifesciences Limited Net Profit
Year Net Profit Growth
2013 53.571.000
2014 65.193.000 17.83%
2015 6.384.000 -921.19%
2016 -18.670.000 134.19%
2017 -54.085.000 65.48%
2018 107.000 50646.73%
2019 7.464.000 98.57%
2019 8.091.000 7.75%
2020 33.100.000 75.56%
2021 277.300.000 88.06%
2022 87.461.000 -217.06%
2023 -159.776.000 154.74%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Austar Lifesciences Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Austar Lifesciences Limited Free Cashflow
Year Free Cashflow Growth
2013 60.358.000
2014 -76.169.999 179.24%
2015 47.352.000 260.86%
2016 -41.476.000 214.17%
2017 -15.268.000 -171.65%
2018 -82.784.000 81.56%
2019 24.068.000 443.96%
2019 5.783.500 -316.15%
2020 25.684.000 77.48%
2021 -204.022.000 112.59%
2022 -155.253.000 -31.41%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Austar Lifesciences Limited Operating Cashflow
Year Operating Cashflow Growth
2013 71.407.000
2014 -64.400.999 210.88%
2015 61.526.000 204.67%
2016 -30.462.000 301.98%
2017 -6.171.000 -393.63%
2018 -77.598.000 92.05%
2019 37.793.000 305.32%
2019 9.448.250 -300%
2020 52.224.000 81.91%
2021 -103.451.000 150.48%
2022 -37.926.000 -172.77%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Austar Lifesciences Limited Capital Expenditure
Year Capital Expenditure Growth
2013 11.049.000
2014 11.769.000 6.12%
2015 14.174.000 16.97%
2016 11.014.000 -28.69%
2017 9.097.000 -21.07%
2018 5.186.000 -75.41%
2019 13.725.000 62.21%
2019 3.664.750 -274.51%
2020 26.540.000 86.19%
2021 100.571.000 73.61%
2022 117.327.000 14.28%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Austar Lifesciences Limited Equity
Year Equity Growth
2013 128.375.000
2014 549.056.000 76.62%
2015 550.984.000 0.35%
2016 546.115.000 -0.89%
2017 480.387.000 -13.68%
2018 482.923.000 0.53%
2019 502.624.999 3.92%
2020 524.574.000 4.18%
2021 788.420.000 33.47%
2022 883.581.000 10.77%
2023 775.473.000 -13.94%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Austar Lifesciences Limited Assets
Year Assets Growth
2013 606.853.000
2014 869.390.000 30.2%
2015 960.985.000 9.53%
2016 914.776.000 -5.05%
2017 881.567.000 -3.77%
2018 1.071.369.999 17.72%
2019 1.174.322.000 8.77%
2020 1.378.844.000 14.83%
2021 2.044.777.000 32.57%
2022 2.388.763.000 14.4%
2023 2.158.972.000 -10.64%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Austar Lifesciences Limited Liabilities
Year Liabilities Growth
2013 478.478.000
2014 320.334.000 -49.37%
2015 410.001.000 21.87%
2016 368.661.000 -11.21%
2017 401.180.000 8.11%
2018 588.447.000 31.82%
2019 671.697.000 12.39%
2020 854.270.000 21.37%
2021 1.256.357.000 32%
2022 1.505.182.000 16.53%
2023 1.383.499.000 -8.8%

Austar Lifesciences Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.93
Net Income per Share
-0.08
Price to Earning Ratio
-9.76x
Price To Sales Ratio
0.42x
POCF Ratio
-6.02
PFCF Ratio
-4.03
Price to Book Ratio
0.5
EV to Sales
0.76
EV Over EBITDA
-14.37
EV to Operating CashFlow
-11.3
EV to FreeCashFlow
-7.38
Earnings Yield
-0.1
FreeCashFlow Yield
-0.25
Market Cap
0,40 Bil.
Enterprise Value
0,73 Bil.
Graham Number
1.67
Graham NetNet
-0.69

Income Statement Metrics

Net Income per Share
-0.08
Income Quality
1.62
ROE
-0.05
Return On Assets
-0.02
Return On Capital Employed
-0.06
Net Income per EBT
0.57
EBT Per Ebit
1.19
Ebit per Revenue
-0.06
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0.09
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.15
Operating Profit Margin
-0.06
Pretax Profit Margin
-0.07
Net Profit Margin
-0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.13
Free CashFlow per Share
-0.2
Capex to Operating CashFlow
-0.53
Capex to Revenue
0.04
Capex to Depreciation
1.92
Return on Invested Capital
-0.05
Return on Tangible Assets
-0.02
Days Sales Outstanding
376.51
Days Payables Outstanding
181.35
Days of Inventory on Hand
108.63
Receivables Turnover
0.97
Payables Turnover
2.01
Inventory Turnover
3.36
Capex per Share
0.07

Balance Sheet

Cash per Share
0,35
Book Value per Share
1,55
Tangible Book Value per Share
1.34
Shareholders Equity per Share
1.55
Interest Debt per Share
0.99
Debt to Equity
0.64
Debt to Assets
0.23
Net Debt to EBITDA
-6.52
Current Ratio
1.34
Tangible Asset Value
0,67 Bil.
Net Current Asset Value
0,19 Bil.
Invested Capital
882455000
Working Capital
0,40 Bil.
Intangibles to Total Assets
0.05
Average Receivables
1,01 Bil.
Average Payables
0,43 Bil.
Average Inventory
286359500
Debt to Market Cap
1.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Austar Lifesciences Limited Dividends
Year Dividends Growth
2015 0

Austar Lifesciences Limited Profile

About Austar Lifesciences Limited

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.

CEO
Mr. Kwok Keung Ho
Employee
1.492
Address
Rooms 2010-2013
Shanghai,

Austar Lifesciences Limited Executives & BODs

Austar Lifesciences Limited Executives & BODs
# Name Age
1 Mr. Kwok Keung Ho
Founder, Chairman of the Board & Chief Executive Officer
70
2 Ms. Yuk Kiu Mak
Company Secretary
70
3 Madam Xiangdi Tang
Vice President of Corporate Development
70
4 Mr. Yuewu Chen
Executive Director
70
5 Madam Ning Zhou
Executive Director
70
6 Mr. Kin Hung Ho
Executive Director
70

Austar Lifesciences Limited Competitors